Ocelot Bio
Ocelot Bio
ocelotbio.com

Locations

San Diego, CA, USA

industry

Biotechnology

Size

1 - 10 employees

Stage

Other

founded in

2020

Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a therapeutic peptide with a mechanism of action designed to selectively address portal hypertension induced complications of end-stage liver disease (ESLD). These complications include hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites, both of which may lead to serious and life-threatening outcomes. Ocelot Bio has initiated a Phase 2 clinical trial of OCE-205 in HRS-AKI, and the U.S. Food & Drug Administration (FDA) has granted OCE-205 orphan drug designation in the treatment of hepatorenal syndrome. The company was founded by leading experts in therapeutic peptide development and is backed by a strong syndicate of investors including Venrock, RA Capital Management, and Vivo Capital. For more information, visit www.ocelotbio.com.

Something looks off?
Open jobs at Ocelot Bio
This company does not have jobs relevant to this job board at this time.
To view all their jobs, visit their website.